SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance.

Jensen-Pergakes, K; Tatlock, J; Maegley, K; McAlpine, I; McTigue, M; Xie, T; Dillon, C; Wang, YL; Yamazaki, S; Spiegel, N; Shi, ML; Nemeth, A; Miller, N; Hendrickson, E; Lam, H; Sherrill, J; Liu, W; Deng, YL; Chung, CY; McMillan, EA; Palde, P; Brooun, A; Braganza, J; Kephart, SE; Kumpf, R; Patman, R; Rui, E; Scales, S; Tran-Dube, M; Wang, F; Wythes, M; Paul, T

CANCER RESEARCH, 2021; 81 (13):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索